

Correction

Correction: Marceau, F. Drugs of the Kallikrein–Kinin System: An Overview. *Drugs Drug Candidates* 2023, 2, 538–553

François Marceau 

Axe Microbiologie-Infectiologie et Immunologie, Research Center, CHU de Québec-Université Laval, Québec, QC G1V 4G2, Canada; francois.marceau@crchudequebec.ulaval.ca

In the original publication [1], there were mistake in Tables 3 and 4 as published.

Error in Table 3

In the original publication, there was a mistake in Table 3 as published. In the line starting with “Diabetic macula edema”, the highlighted and italicized number should have been 9, not 8.

Error in Table 4

In the original publication, there was a mistake in Table 4 as published. In the line dealing with breast cancer, “NPA” should have been replaced with “agonist”.

The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.

Reference

1. Marceau, F. Drugs of the Kallikrein–Kinin System: An Overview. *Drugs Drug Candidates* 2023, 2, 538–553. [[CrossRef](#)]

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.



Citation: Marceau, F. Correction: Marceau, F. Drugs of the Kallikrein–Kinin System: An Overview. *Drugs Drug Candidates* 2023, 2, 538–553. *Drugs Drug Candidates* 2024, 3, 208. <https://doi.org/10.3390/ddc3010012>

Received: 23 January 2024

Accepted: 29 January 2024

Published: 22 February 2024



Copyright: © 2024 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).